{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:44:34Z","timestamp":1792115074357,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaci.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:32:45Z","timestamp":1782851565000},"page":"727-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab outcomes in pediatric asthma by early eosinophil status: Post hoc analysis of VOYAGE\/EXCURSION"],"prefix":"10.1016","volume":"158","author":[{"given":"Sharon","family":"Dell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa W.","family":"Guilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Deschildre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare S.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Moraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.06.012_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.012_bib4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.06.012_bib5","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2026.06.012_bib6","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2026.06.012_bib7","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.012_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(23)00303-X","article-title":"Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study","volume":"12","author":"Bacharier","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.06.012_bib9","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.06.012_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaci.2025.07.037","article-title":"Transient early blood eosinophil increases do not affect dupilumab\u2019s long-term efficacy in patients with moderate-to-severe asthma","volume":"157","author":"Pavord","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.012_bib11","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00431-023-04961-x","article-title":"Eosinophilia in children: characteristics, etiology and diagnostic algorithm","volume":"182","author":"Cetinkaya","year":"2023","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaci.2026.06.012_bib12","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3389\/fimmu.2018.01944","article-title":"An approach to the evaluation of persistent hypereosinophilia in pediatric patients","volume":"9","author":"Schwartz","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.06.012_bib13","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/all.16610","article-title":"Dupilumab and blood eosinophilia: a disease-specific phenomenon?","volume":"80","author":"Portacci","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.06.012_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/biom14050546","article-title":"The possible roles of IL-4\/IL-13 in the development of eosinophil-predominant severe asthma","volume":"14","author":"Nakagome","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaci.2026.06.012_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s10875-025-01914-x","article-title":"Dupilumab-induced eosinophilic granulomatosis with polyangiitis complicated by peripheral neuropathic pain: a case report and literature review","volume":"45","author":"Wu","year":"2025","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.012_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaip.2024.11.014","article-title":"Dupilumab efficacy and safety in children with moderate to severe asthma and high blood eosinophils: a post hoc analysis of VOYAGE","volume":"13","author":"Jackson","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jaci.2026.06.012_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.012_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.06.012_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000537833","article-title":"Normal blood eosinophil counts in humans","volume":"103","author":"Lommatzsch","year":"2024","journal-title":"Respiration"},{"key":"10.1016\/j.jaci.2026.06.012_bib20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2213-2600(25)00174-2","article-title":"Eosinophils in asthma phenotypes: perpetrators or guilty by association?","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.06.012_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00048-2024","article-title":"Dupilumab-associated hypereosinophilia in severe asthma","volume":"10","author":"Strong","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaci.2026.06.012_bib22","first-page":"843","article-title":"An updated reappraisal of dupilumab in children and adolescents with severe asthma","volume":"11","author":"Marseglia","year":"2024","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jaci.2026.06.012_bib23","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.3390\/jcm14093153","article-title":"Biologic therapies for severe asthma: current insights and future directions","volume":"14","author":"Faria","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2026.06.012_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/hematology.2022000367","article-title":"Approach to the patient with suspected hypereosinophilic syndrome","volume":"2022","author":"Klion","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaci.2026.06.012_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/ACI.0000000000001078","article-title":"Hypereosinophilia: clinical and therapeutic approach in 2025","volume":"25","author":"Taurisano","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.012_bib26","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1111\/all.14964","article-title":"Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia","volume":"76","author":"Lommatzsch","year":"2021","journal-title":"Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492600446X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492600446X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:50:25Z","timestamp":1792111825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492600446X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S009167492600446X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.06.012","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab outcomes in pediatric asthma by early eosinophil status: Post hoc analysis of VOYAGE\/EXCURSION","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}